Title

- A study to assess the impact of cobas Liat point-of-care PCR assays (SARS-CoV-2 and
- Influenza A/B) on patient clinical management in the emergency department of the
- University of California at Davis Medical Center

Authors

6 Larissa May, 1 Elissa M. Robbins, 2 Jesse A. Canchola, 2 Kamal Chugh, 2 Nam K. Tran 3

Affiliations

- 8 ¹ Department of Pathology and Laboratory Medicine, University of California, Davis,
- Sacramento, California, USA
- 10 ² Roche Molecular Systems, Pleasanton, California, USA
- ³ Department of Emergency Medicine, University of California, Davis, Sacramento, California,
- USA

Corresponding author

- Nam K. Tran
- University of California, Davis,
- CA 95616, USA
- Tel: 530-752-7355
- E-Mail: nktran@UCDAVIS.EDU

Running head

Use of cobas Liat SARS-CoV-2 and Influenza A/B assays

Author contributions

- NKT, EMR, and LM were involved in the conception and design of the work, data collection,
- and data interpretation. JAC and KC were involved in data analysis and interpretation. All

- authors contributed to the drafting and critical revision of the article and gave their final
- approval of the manuscript to be published.

Abstract

Background

- Rapid detection of SARS-CoV-2 is crucial for reduction of transmission and clinical decision-
- 30 making. The cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas
- 31 Liat[®] System is a rapid (20 minutes) point-of-care (POC) polymerase chain reaction (PCR)
- method.
- *Methods*
- This unblinded, pre-post study enrolled consecutive patients with symptoms/signs consistent
- with SARS-CoV-2 infection presenting to the University of California, Davis emergency

department (ED). Outcomes following implementation of the cobas Liat SARS-CoV-2 &

Influenza A/B test (intervention period: December 2020–May 2021) were compared with

- previous standard-of-care using centralized laboratory PCR methods (control period: April
- 2020–October 2020).

Results

Electronic health records of 8879 symptomatic patients were analyzed, comprising 4339 and 4540 patient visits and 538 and 638 positive SARS-CoV-2 PCR test results in the control and intervention periods, respectively. Compared with the control period, turnaround time (TAT) was shorter in the intervention period (median 0.98 vs 12.3 hours; p<0.0001). ED length of stay (LOS) was generally longer in the intervention period compared with the control period, but for those SARS-CoV-2-negative who were admitted, ED LOS was shorter (median 12.53 vs 17.93 hours; p<0.0001). Overall, the rate of anti-infective prescribing was also lower in the intervention period than in the control period (antibiotics only: 38.11% vs 44.55%; p<0.0001 and antivirals only: 3.13% vs 0.94%; p<0.0001).

Conclusion

- This real-world study confirms faster TAT with a POC PCR method in an emergency care
- setting and highlights the importance of rapid SARS-CoV-2 detection to aid patient
- management and inform treatment decisions.

Clinical Relevance

- This study reports data collected from a quasi-experimental pre-post study using the
- electronic health records of patients presenting to the emergency department (ED) of the
- University of California at Davis Medical Center with symptoms or signs consistent with
- SARS-CoV-2 infection during their ED visit. The primary objective of this study was to
- 59 determine if implementation of the point-of-care (POC) cobas[®] Liat[®] SARS-CoV-2 &
- Influenza A/B test for use on the cobas Liat System reduced the diagnostic turnaround time
- and/or length of stay for ED patients with suspected SARS-CoV-2 infection compared with
- the previous standards of care (batch-wise diagnostic testing using the cobas 6800 System
- 63 and on-demand urgent testing on the GenMark Dx^{\odot} ePlex[®] system in a centralized clinical
- laboratory). Ultimately, these data help to inform how implementation of POC molecular
- testing methods impact patient management.
-

Keywords

SARS-CoV-2; molecular testing; PCR; point-of-care; diagnosis

Introduction

92 typical TATs for high-throughput NAATs can range from ~1.5 hours to 8 hours (14), with approximately 97% of polymerase chain reaction (PCR) results available within 23 hours

from arrival in the ED (13). Symptomatic patients should be isolated in an examination room or designated area, in the absence of a laboratory-confirmed diagnosis, with consequences for allocations of hospital resources, including the need for isolation bays and personal protective equipment (15, 16). Given the implications for infection prevention, and the variability in isolation capacity (16), rapid results are helpful for the effective triage of ED patients with suspected SARS-CoV-2, both to reduce transmission and to identify those that may benefit from hospital admission or other therapeutic intervention (4). Further, performing on-demand POC testing in the ED while using centralized high-throughput systems for less urgent testing needs could increase overall testing capacity. At the onset of this study, the University of California (UC) at Davis Medical Center 104 performed diagnostic testing in a centralized clinical laboratory. The cobas[®] Liat[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas Liat System (cobas Liat SARS-CoV-2 & Influenza A/B test) is intended for the simultaneous rapid *in vitro* detection and differentiation of SARS-CoV-2 and influenza A and B virus nucleic acids in clinical specimens from individuals suspected of respiratory viral infection (17). The assay provides results from a single test to rule-in or rule-out influenza and COVID-19 simultaneously, within approximately 20 minutes (17). The primary objective of this study was to determine if implementation of the cobas Liat SARS-CoV-2 & Influenza A/B test reduced the diagnostic assay TAT and/or length of stay (LOS) for ED patients with suspected SARS-CoV-2 infection compared with the previous 114 standards of care. The secondary objectives were to determine the impact of POC testing on

ED disposition and the use of anti-infectives in patient management.

Materials and Methods

Study design

This was a retrospective, unblinded, quasi-experimental pre-post study The study comprised

- two periods: a control period (April 01, 2020 to October 31, 2020) and an intervention period
- (December 01, 2020 to May 31, 2021).

Participants

- Individuals presenting at the UC Davis ED were included in the study consecutively if they
- had symptoms or signs consistent with COVID-19 at their ED visit (**Supplementary Table**
- **S1**). A real-time reverse transcriptase PCR (RT-PCR) SARS-CoV-2 test must also have
- been ordered by the ED physician during the patient's ED visit, in either study period. For
- each patient included in the study, the information of a complete event, defined as all
- diagnostics and prescriptions ordered within 30 days of the initial ED visit, was collected
- using electronic health records.

Sample collection, storage and testing

Samples were collected according to manufacturer instructions and analyzed as soon as possible, not exceeding maximum storage times and temperatures dictated by the manufacturer's instructions for use (IFU) (17-19). In the control period, centralized diagnostic testing was conducted using the cobas SARS-CoV-2 test on the cobas 6800 System (19) or 134 on-demand urgent testing using the GenMark Dx° ePlex $^{\circ}$ SARS-CoV-2 Test (18). The cobas 6800 System can perform more than 1000 tests per day, with first results reported in approximately 3 hours of loading (20, 21). In contrast, the assay run time for the ePlex SARS-CoV-2 Test is approximately 90 minutes (22) allowing for up to 288 samples per day (23) depending on instrument configuration and lab staffing. In the intervention period, the cobas Liat SARS-CoV-2 & Influenza A/B test was used for detection of the target sequences (17).

Analysis

For the purpose of this analysis, data from the two centralized testing methods were pooled to allow the comparison between POC PCR and centralized PCR methods. Data collected during November 2020 were excluded from the analysis as this was considered a transition period, allowing a phasing in of the POC assay. Samples yielding indeterminate/invalid results were handled per the assay IFUs (17-19).

- More information on test methods and analysis is available in the **Supplementary**
- **Materials**.
- *Statistical analysis*

No formal sample size calculations were conducted for this study. All data analyses were

151 performed using $SAS/STAT^{\circ}$ v9.4 software (24). Comparisons were made at the patient

visit-level rather than continuously over the study duration. Patient data included in this study

were summarized using descriptive statistics and compared between the control and

intervention periods. The primary endpoints of TAT and LOS, and the secondary endpoints

of ED disposition and anti-infective prescription rates, were also analyzed by SARS-CoV-2

test result. A post hoc analysis of LOS and anti-infective use was conducted to stratify data

by ED disposition and by SARS-CoV-2 test result and ED disposition.

Statistical hypothesis testing was performed using the Chi-Square test for categorical data,

the non-parametric Wilcoxon rank-sum test for continuous-level non-normally distributed

- data and the Student's t-test for normally distributed data. The rate of type I errors was
- controlled for using the false discovery rate method when conducting multiple comparisons.
- Indeterminate/invalid results were combined and included in the relevant tables but were not
- included in statistical hypothesis testing due to small sample sizes.

Ethics statement

- This study was conducted in compliance with the International Conference on Harmonisation
- Good Clinical Practice Guidelines, and applicable US Food and Drug Administration
- regulations. The study protocol and de-identification procedure for patient data were
- approved by the UC Davis Institutional Review Board Administration.
- *Data availability*
- The data used to support the findings of this study are included within the article and
- supplementary materials.

Results

- *Patient demographics and characteristics*
- A total of 8879 medical records were included in the study (**Supplementary** Error!
- Reference source not found.). Patient demographics were similar (all comparisons, p>0.05)
- in the control and intervention cohorts (**Table 1**) and were therefore not controlled for in
- subsequent analyses. Across both periods, mean patient age was 47 years (median 51
- years), the majority were White (42.03%), and 48.64% were female. Almost 40% of patients
- 179 had a body mass index below the cut-off for obesity (\langle 30.0 kg/m²) (25).
- The most commonly recorded SARS-CoV-2-related symptom was shortness of
- breath/difficulty breathing (21.83% control period, 18.57% intervention period)
- (**Supplementary Table S1**). Only one symptom was recorded for 54.51% of patients in
- 183 control period and 47.97% in the intervention period), with 2 or ≥3 symptoms reported by
- <3% of patients each in either period (**Supplementary Table S2**).
- More SARS-CoV-2 PCR tests were conducted in the intervention period than in the control
- period (n=4540 vs n=4339), and of those, more tested positive in the intervention period
- (14.05% vs 12.40%, respectively). Twelve (0.28%) tests were recorded as invalid/other in

the control period versus none in the intervention period (**Supplementary Table S3**; p<0.02

- overall for test outcome between periods).
- *Impact of rapid POC testing on TAT*
- The TAT (defined here as time from electronic SARS-CoV-2 test order to result reporting)
- was shorter in the intervention period compared with the control period (median 0.98 vs 12.3
- hours; p<0.0001) (**Table 2**). The lower end of the range for TAT in the control period (range
- 1.92, 74.38 hours) likely reflects samples analyzed with the ePlex SARS-CoV-2 Test, which

has a shorter TAT than the cobas 6800. TAT was similarly reduced in the intervention period

- when analyzed by SARS-CoV-2 test result (**Table 2**) and when TAT was calculated as the
- time from sample collection to result reporting (**Supplementary Table S4**).
- *Impact of rapid POC testing on ED LOS*
- Median ED LOS was longer in the intervention period (7.56 vs 7.15 hours; p=0.02) and for
- patients positive for SARS-CoV-2 (p<0.0001) (**Table 3**). ED LOS was similar in both periods
- 201 for patients negative for SARS-CoV-2. By ED disposition, median LOS was longer in the
- 202 intervention period for those who were discharged after ED care (5.10 hours vs 4.43 hours;
- p<0.0001) but shorter for those admitted (13.50 hours vs 18.48 hours; p<0.0001). ED LOS
- was similar in both periods for those who were admitted to the intensive care unit (ICU) or
- who died (both p>0.05) (**Table 3**).
- By SARS-CoV-2 test result and ED disposition, median ED LOS was longer in the
- intervention period for those who were discharged, regardless of test result (both p<0.0001)
- (**Supplementary Table S5**). For those admitted, median ED LOS was longer in the
- 209 intervention period for patients with a positive SARS-CoV-2 result (p=0.02) and shorter with
- a negative result (p<0.0001).

Hospital LOS was similar between study periods overall and when analyzed by SARS-CoV-2

result (all comparisons, p>0.05; **Supplementary Table S6**). ICU LOS was shorter in the

- intervention period compared with the control period overall (2.08 days vs 2.49 days;
- p=0.01) and for those with a negative SARS-CoV-2 result (p=0.01) (**Supplementary Table**
- **S7**). Patients with a positive SARS-CoV-2 result had a similar ICU LOS in both periods
- (p>0.05).
- *Impact of rapid POC testing on ED disposition*
- Fewer patients were admitted to the ICU in the intervention period (11.78%) compared with
- the control period (14.22%; p=0.0026) (**Table 4**). Patients with a positive SARS-CoV-2 result
- 220 in the intervention period were more likely to be admitted to the hospital ($p=0.0002$) and less
- likely to be discharged (p=0.0002). Conversely, patients who tested negative were less likely
- 222 to be admitted to the ICU in the intervention period (p=0.0006).
- *Impact of rapid POC testing on antibiotic/antiviral use*
- Antibiotic-only use was 14.5% lower in the intervention period (38.11% vs 44.55%;
- p<0.0001; **Table 5**), and the magnitude of the change was greater in patients with a positive
- vs negative SARS-CoV-2 result (47.2% vs 10.6% reduction; p<0.0001 for both). Antiviral-
- 227 only use was higher in the intervention period compared with the control period (3.13% vs
- 0.94%; p<0.0001). Antivirals were prescribed more in the intervention period when patients
- were SARS-CoV-2 positive (14.89%) than when negative (0.92%). Approximately half of
- 230 patients received no antibiotic or antiviral in both periods, though a higher proportion of
- patients received neither in the intervention period (54.25% vs 49.97%; p<0.0001).
- Patterns of anti-infective prescription were similar when analyzed by ED disposition (**Table**
- **5**). However, as would be expected based on prescribing requirements, greater prescription
- of antivirals in the intervention period compared with the control period was more evident in
- those admitted to hospital or the ICU. By SARS-CoV-2 test result and ED disposition

(**Supplementary Table S8**), antibiotic-only use in the intervention period compared with the control period was considerably lower in positive patients who were discharged or admitted (both p<0.0001). For SARS-CoV-2-negative patients, antibiotic prescriptions were similar in both periods for those who were discharged (p>0.05) but lower in the intervention period for 240 those who were admitted to hospital $(p=0.01)$.

Summaries of antibiotic and antiviral prescription rates by month are available in

Supplementary Tables S9 and S10, respectively.

Discussion

In this large study, ED patients with signs or symptoms consistent with COVID-19 received POC PCR test results in under an hour, compared with approximately 12 hours for centralized tests, when averaged across the cobas SARS-CoV-2 test and ePlex Test. The faster TAT did not reduce median ED LOS overall but did appear to reduce ED LOS for 248 patients with negative test results who were subsequently admitted, suggesting more effective patient triage. The rate of antibiotic prescribing was also lower in the intervention period than in the control period overall, and in the population of patients with a positive SARS-CoV-2 result, which could support improved antibiotic stewardship with faster diagnosis.

Previous studies have evaluated the clinical performance of the cobas Liat SARS-CoV-2 & 254 Influenza A/B test compared with other RT-PCR systems, such as the Cepheid® GeneXpert \degree system[®] (26) and the cobas SARS-CoV-2 test on the cobas 6800/8800 Systems (27), and have demonstrated 100% positive percent agreement and 97–100% negative percent agreement. One study, conducted in an ED in Germany, estimated that POC PCR results using the cobas Liat System were available after 102 minutes from admission, which was shorter than the 811 minutes with central laboratory PCR (28). Though the TAT observed in

the clinic is longer than the 20-minute assay run time, demonstrating some delay in the 261 testing strategy, time to result is still substantially shorter than for centralized PCR methods.

Fast TAT with a reliable POC PCR assay for respiratory pathogens can reduce ED LOS (29). However, as in our study, some have reported increased ED LOS following the introduction of rapid diagnostic tests (30, 31). It is likely that factors other than TAT, such as availability of hospital resources (including number of isolation rooms), severity of symptoms, and presence of comorbidities requiring further work-up, contribute to longer ED LOS (30, 31). In this study, the ED had a higher number of symptomatic patient visits and positive SARS-CoV-2 test results in the intervention period than in the control period, likely related to the emergence of several SARS-CoV-2 variants, most notably Delta, diving surges (32), 270 which may have contributed to increased LOS in the intervention period. Despite this, we found that ED LOS for patients with negative test results who were admitted was shorter following POC PCR implementation, indicating more effective patient triage. Across both study periods, approximately 50% of ED patients were discharged and 37% were admitted. Though ICU admissions were lower in the intervention period, this result should be interpreted with care. Lower ICU admissions could indicate improved patient triage and management, which would have cost-saving implications (33, 34), but it is possible that patients in the control period had a variant associated with more severe disease (35), or that the reduction was due to other changes in hospital practices. Admission rates appeared higher than in other studies of symptomatic patients who were PCR tested for SARS-CoV-2, where admission rates were approximately 27–28% (36, 37). Higher admission rates could reflect the severity of symptoms encountered in this cohort, differences in hospital practices, or factors such as comorbidities that have not been

controlled for. The UC Davis Medical Center is also a quaternary referral center, and the ED

serves as a safety net for vulnerable populations and those with comorbidities of concern.

Several studies have demonstrated that implementing rapid POC PCR tests can improve clinical decision-making and management of patients with respiratory infections (27, 38, 39). Shorter time to diagnosis can reduce inappropriate antibiotic prescribing and allow for appropriate de-escalation (29, 38-41). Within the first 6 months of the pandemic, antibiotic prescribing rates for patients with COVID-19 was high (almost 75%), even in the absence of bacterial co-infection (42). In our study, though antibiotics were frequently prescribed, the 291 rate was lower in the intervention period than in the control period, particularly in those with a positive SARS-CoV-2 result, supporting the notion that reduced time to result can improve antibiotic stewardship and help slow the emergence of antibiotic resistance (43, 44). Antiviral use was higher in the intervention period, though prescribing rates were low (<5%), likely reflecting the availability of antivirals and the stringent prescribing requirements at the time of 296 the study.

One of the major limitations of this study is that due to the real-word, pre-post study design, several epidemiological factors could not be controlled for. The control and intervention periods were very different in terms of the stage of the COVID-19 pandemic. The control period coincided largely with the first wave, which peaked at approximately 10,000 new cases/day in mid-July (45). The intervention period was initiated in November, which was the start of a surge in cases in California, with approximately 47,000 new cases/day at the end of December and >100,000 cases/day in January (45). The study may also have been impacted by seasonality, with higher rates of respiratory infections generally encountered in winter (the intervention period) (46). In addition to environmental factors, COVID-19 treatment guidelines or practices were rapidly evolving (47, 48), and the availability of effective treatments changed over time (49), making clinical comparisons challenging. Though the demographics of our patient population were not statistically different between periods, other non-collected characteristics of patients presenting to the ED may have differed (50), particularly as ED volumes were low during the beginning of the pandemic.

Nevertheless, this study provides an important insight into the outcomes observed following the implementation of a rapid POC SARS-CoV-2 test at a time when new cases of COVID-19 were high. It is also important to note that while our study supports the use of POC PCR tests in an emergency care setting, high-throughput centralized testing for SARS-CoV-2 remains an important diagnostic tool for patients not in need of immediate results. In this 316 study, system identifiers were missing from the dataset, so it was not possible to analyze TAT for the cobas 6800 or ePlex systems separately; however, it is recognized that TAT using the ePlex SARS-CoV-2 Test is shorter than the cobas SARS-CoV-2 test. The ability to perform tests on the cobas Liat System, or other POC platforms, may increase capacity for testing to be conducted on centralized systems with broader respiratory pathogen testing panels, potentially improving testing efficiency and antibiotic prescribing practices.

Conclusion

- In conclusion, this study confirms that the cobas Liat SARS-CoV-2 & Influenza A/B test
- provides a considerably shorter TAT compared with centralized laboratory PCR methods,
- particularly those using sample batching, in a real-world emergency care setting. Decreased
- TAT also has the potential to reduce ED LOS in some patient populations and allows for
- better patient management and informed treatment decisions, in-line with improved antibiotic
- stewardship.

Funding

This study was funded by Roche Molecular Systems, Inc.

Disclosures

- EMR, JAC, and KC are employees of Roche Molecular Systems Inc., and EMR holds
- company stock. LM and NKT have received payment or honoraria for lectures,

- presentations, or advisory boards from Roche Molecular Systems, Inc., and LM has received
- honoraria from Roche Diagnostics Solutions.

Acknowledgements

- The authors would like to thank Christopher Dodoo of Roche Molecular Systems, Inc.,
- Pleasanton, California, USA, who contributed statistical support; Jeffrey Flack of University
- of California, Davis, California, USA for support with dataset creation; and Babar Javed of
- Roche Molecular Systems, Inc., Pleasanton, California, USA, who was the study manager.
- Medical writing support was provided by Samantha Forster of Elements Communications Ltd
- (Westerham, UK) and was funded by Roche Molecular Systems, Inc.
- In the US, the cobas SARS-CoV-2 & Influenza A/B test (17) is only for use under the Food
- and Drug Administration's Emergency Use Authorization. COBAS, LIAT, EPLEX and
- GENMARK DX are trademarks of Roche. All other product names and trademarks are the
- 347 property of their respective owners.

349 **References**

- 350 1. Centers for Disease Control and Prevention. 2022. COVID data tracker. 351 https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 09 May 2022. 352 2. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, Derqui-353 Fernandez N, Barnett JL, Whitfield MG, Varro R, Charlett A, Kundu R, Fenn J, Cutajar 354 J, Quinn V, Conibear E, Barclay W, Freemont PS, Taylor GP, Ahmad S, Zambon M, 355 Ferguson NM, Lalvani A. 2022. Community transmission and viral load kinetics of the 356 SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in 357 the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 22:183–195. 358 3. Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, 359 Diggle PJ, Page AJ, Trotter AJ, Prosolek SJ, Ashby D, Donnelly CA, Barclay W, Taylor 360 G, Cooke G, Ward H, Darzi A, Riley S. 2021. Exponential growth, high prevalence of 361 SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science 362 374:eabl9551. 363 4. Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos Ferreira 364 CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic test: challenges 365 and key considerations for the future. Crit Rev Clin Lab Sci 366 doi:10.1080/10408363.2022.2045250:1–15.
- 367 5. Cabinet Office. 2022. Guidance: COVID-19 response: living with COVID-19, on
368 Gov.uk. https://www.gov.uk/government/publications/covid-19-response-living-368 Gov.uk. https://www.gov.uk/government/publications/covid-19-response-living-with-369 covid-19/covid-19-response-living-with-covid-19. Accessed 26 May 2022.
- 370 6. Centers for Disease Control and Prevention. 2021. Public health recommendations 371 for fully vaccinated people. https://www.cdc.gov/media/releases/2021/p0308-372 vaccinated-guidelines.html. Accessed 26 May 2022.
- 373 17. Israel Ministry of Health. 2021. Israel to life all Coronavirus restrictions, on Gov.il.
374 https://www.gov.il/en/departments/news/23052021-02. Accessed 26 May 2022. https://www.gov.il/en/departments/news/23052021-02. Accessed 26 May 2022.
- 375 8. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen 376 C, Fry AM. 2020. Decreased influenza activity during the COVID-19 pandemic - 377 United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep 378 69:1305-1309.
- 379 9. Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, Le H, Levy 380 A, Moore HC, Blyth CC. 2021. The interseasonal resurgence of respiratory syncytial 381 virus in Australian children following the reduction of coronavirus disease 2019– 382 related public health measures. Clinical Infectious Diseases 73:e2829-e2830.
- 383 10. Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, Matsubayashi K, 384 Hattori S, Taniguchi C. 2022. Shorter incubation period among COVID-19 cases with 385 the BA.1 Omicron variant. Int J Environ Res Public Health 19:6330.

- 386 11. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim 387 AS. 2022. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of 388 concern and its global perspective. J Med Virol 94:1738-1744.
- 389 12. Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ, Skoetz N, Estcourt 390 L, McQuilten ZK, Wood EM, Khoury DS, Davenport MP. 2022. Determinants of 391 passive antibody effectiveness in SARS-CoV-2 infection. medRxiv 392 doi:10.1101/2022.03.21.22272672:2022.03.21.22272672.
- 393 13. Soltan AAS, Yang J, Pattanshetty R, Novak A, Yang Y, Rohanian O, Beer S, Soltan 394 MA, Thickett DR, Fairhead R, Zhu T, Eyre DW, Clifton DA, Collaborative CT. 2022. 395 Real-world evaluation of rapid and laboratory-free COVID-19 triage for emergency 396 care: external validation and pilot deployment of artificial intelligence driven 397 screening. Lancet Digit Health 4:e266-e278.
- 398 14. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020. 399 Comparison of the analytical sensitivity of seven commonly used commercial SARS-400 CoV-2 automated molecular assays. J Clin Virol 130:104578.
- 401 15. Dancer SJ. 2021. Reducing the risk of COVID-19 transmission in hospitals: focus on 402 additional infection control strategies. Surgery (Oxford, Oxfordshire) 39:752-758.
- 403 16. El Tawil C, El Hussein M, Souaiby N, Helou M. 2022. Emergency department 404 management of COVID-19 suspected patients. An international perspective. Int J 405 Public Health 67:1604534.
- 406 17. Roche Molecular Systems Inc. 2022. Instructions for use: cobas® SARS-CoV-2 & 407 Influenza A/B Nucleic acid test for use on the cobas® Liat® System. v3.0.
- 408 18. GenMark Diagnostics I. 2020. ePlex®SARS-CoV-2 Test assay manual. 409 https://www.fda.gov/media/136282/download. Accessed 31 May 2022.
- 410 19. Roche Molecular Systems. 2022. Instructions for use: cobas® SARS-CoV-2: 411 qualitative assay for use on the cobas® 6800/8800 Systems v8.0.
- 412 20. Roche molecular Systems I. 2015. cobas® 6800/8800 Systems: systems 413 specifications.
- 414 21. UC Davis Health News. 2020. UC Davis Health speeds up COVID-19 testing. 415 https://health.ucdavis.edu/news/headlines/uc-davis-health-speeds-up-covid-19- 416 testing/2020/04. Accessed 23 Jun 2022.
- 417 22. Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical evaluation of three 418 sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol 58:e00783- 419 20.
- 420 23. Roche Diagnostics Limited. 2022. Product information: ePlex® System. 421 https://diagnostics.roche.com/global/en/products/systems/eplex-system.html. 422 Accessed 4 August 2022.

- 423 24. SAS Institute Inc. 2013. The SAS®System for Linux, v9.4. Cary, NC, USA.
- 424 25. Centers for Disease Control and Prevention. 2022. Defining adult overweight and 425 obesity https://www.cdc.gov/obesity/basics/adult-defining.html. Accessed 7 June 426 2022.
- 427 26. Tsang HF, Leung WMS, Chan LWC, Cho WCS, Wong SCC. 2021. Performance 428 comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-429 2 detection in nasopharyngeal swab and posterior oropharyngeal saliva. Expert Rev 430 Mol Diagn 21:515–518.
- 431 27. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, Jin R, 432 Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical performance of 433 the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter 434 study. J Clin Microbiol 59:e02811-20.
- 435 28. Möckel M, Bolanaki M, Hofmann J, Stein A, Hitzek J, Holert F, Fischer-Rosinský A, 436 Slagman A. 2022. SARS-CoV-2 screening in patients in need of urgent inpatient 437 treatment in the Emergency Department (ED) by digitally integrated point-of-care 438 PCR: a clinical cohort study. Diagn Microbiol Infect Dis 102:115637.
- 439 29. Egilmezer E, Walker GJ, Bakthavathsalam P, Peterson JR, Gooding JJ, Rawlinson W, 440 Stelzer-Braid S. 2018. Systematic review of the impact of point-of-care testing for 441 influenza on the outcomes of patients with acute respiratory tract infection. Rev Med 442 Virol 28:e1995.
- 443 30. Jeong HW, Heo JY, Park JS, Kim WJ. 2014. Effect of the influenza virus rapid antigen 444 test on a physician's decision to prescribe antibiotics and on patient length of stay in 445 the emergency department. PLoS One 9:e110978-e110978.
- 446 31. Jun S-H, Kim J-Y, Yoon Y-H, Lim C-S, Ch H-J, Choi S-H. 2016. The effect of the rapid 447 antigen test for influenza on clinical practice in the emergency department: a 448 comparison of periods before and after the 2009 H1N1 influenza pandemic. Signa 449 Vitae 11:74-89.
- 450 32. Our World in Data. 2022. Share of SARS-CoV-2 sequences that are the delta variant. 451 https://ourworldindata.org/coronavirus#coronavirus-country-profiles. Accessed 4 July 452 2022.
- 453 33. Ohsfeldt RL, Choong CK, Mc Collam PL, Abedtash H, Kelton KA, Burge R. 2021. 454 Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther 455 38:5557-5595.
- 456 34. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, Malhotra D, Emir B, 457 Sung AH, Hammond JL, Stoychev S, Charos A. 2021. Health outcomes and economic 458 burden of hospitalized COVID-19 patients in the United States. J Med Econ 24:308- 459 317.
- 460 35. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. 2021. Novel SARS-CoV-2 461 variants: the pandemics within the pandemic. Clin Microbiol Infect 27:1109-1117.

- 462 36. McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, 463 Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, 464 Villanueva M, Churchwell K, Hsiao A, Torre CJ, Jr., Velazquez EJ, Herbst RS, Iwasaki 465 A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. 2021. Clinical characteristics and 466 outcomes for 7,995 patients with SARS-CoV-2 infection. PLoS One 16:e0243291- 467 e0243291.
- 468 37. Russell FM, Wang A, Ehrman RR, Jacobs J, Croft A, Larsen C. 2021. Risk factors 469 associated with hospital admission in COVID-19 patients initially admitted to an 470 observation unit. Am J Emerg Med 46:339-343.
- 471 38. Hansen GT, Moore J, Herding E, Gooch T, Hirigoyen D, Hanson K, Deike M. 2018. 472 Clinical decision making in the emergency department setting using rapid PCR: 473 results of the CLADE study group. J Clin Virol 102:42-49.
- 474 39. van Rijn AL, Nijhuis RHT, Bekker V, Groeneveld GH, Wessels E, Feltkamp MCW, Claas 475 ECJ. 2018. Clinical implications of rapid ePlex® Respiratory Pathogen Panel testing 476 compared to laboratory-developed real-time PCR. Eur J Clin Microbiol Infect Dis 477 37:571–577.
- 478 40. Benirschke RC, McElvania E, Thomson RB, Jr., Kaul KL, Das S. 2019. Clinical impact 479 of rapid point-of-care PCR influenza testing in an urgent care setting: a single-center 480 study. J Clin Microbiol 57:e01281-18.
- 481 41. Pedersen CJ, Rogan DT, Yang S, Quinn JV. 2018. Using a novel rapid viral test to 482 improve triage of emergency department patients with acute respiratory illness 483 during flu season. J Clin Virol 108:72-76.
- 484 42. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, 485 MacFadden DR. 2021. Antibiotic prescribing in patients with COVID-19: rapid review 486 and meta-analysis. Clin Microbiol Infect 27:520-531.
- 487 43. World Health Organization. 2012. The evolving threat of antimicrobial resistance: 488 options for action, on World Health Organization.
489 https://apps.who.int/iris/handle/10665/44812 Acc https://apps.who.int/iris/handle/10665/44812 Accessed 30 June 2022.
- 490 44. File TM, Jr., Srinivasan A, Bartlett JG. 2014. Antimicrobial stewardship: importance 491 for patient and public health. Clin Infect Dis 59 Suppl 3:S93-S96.
- 492 45. USAFacts. 2022. California coronavirus cases and deaths. 493 https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/state/california. 494 Accessed 9 June 2022.
- 495 46. Price RHM, Graham C, Ramalingam S. 2019. Association between viral seasonality 496 and meteorological factors. Sci Rep 9:929-929.
- 497 47. National Institutes of Health. April 29, 2022 2022. COVID-19 treatment guidelines. 498 https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/guidelines-499 development/. Accessed 13 June 2022.

- 500 48. Lee CK, Merriam LT, Pearson JC, Lipnick MS, McKleroy W, Kim EY. 2022. Treating 501 COVID-19: Evolving approaches to evidence in a pandemic. Cell Rep Med 3:100533.
- 502 49. Cascella M, Rajnik M, Aleem A, Dulebohn SC, R DN. May 4, 2022 2022. Features, 503 evaluation, and treatment of coronavirus (COVID-19), *on* StatPearls Publishing.
504 https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed 15 June 2022. https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed 15 June 2022.
- 505 50. Matsunaga N, Hayakawa K, Asai Y, Tsuzuki S, Terada M, Suzuki S, Ohtsu H, Kitajima 506 K, Toyoda A, Suzuki K, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Nakamura-507 Uchiyama F, Yokota K, Saito F, Izumi K, Sugiura W, Ohmagari N. 2022. Clinical 508 characteristics of the first three waves of hospitalised patients with COVID-19 in 509 Japan prior to the widespread use of vaccination: a nationwide observational study. 510 Lancet Reg Health West Pac 22:100421.

512 Table 1: Patient demographics

513 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

514 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

515 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

- 516 for this study and are included in this summary table.
- 517 ^aChi-square test
- 518 ^bStudent's t-test
- 519 ^cN=58 observations were excluded from the BMI analysis due to data quality issues. BMI cut-off
- 520 based on Centers for Disease Control and Prevention definitions (25)
- 521 ^d Chi-square test excludes 'Other', 'Unknown', or 'Not reported' categories
- 522 ^e Unknown category indicates subjects for whom the corresponding information is not available or
- 523 reported as unknown
- 524 BMI, body mass index; IQR, interquartile range; PCR, polymerase chain reaction; POC, point-of-care;
- 525 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation
- 526

527 Table 2: Summary of SARS-CoV-2 test turnaround time (TAT), order to result

528 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

529 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

530 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

531 for this study and are included in this summary table.

532 ^aWilcoxon rank-sum test

533 **b TAT** was calculated as the difference between test order date–time and result date–time

- 535 ^cTest excludes 'Invalid/other' category
- 536 ^dPCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or ePlex SARS-CoV-2
- 537 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the
- 538 intervention period
- 539 IQR, interquartile range; N/A, not applicable; PCR, polymerase chain reaction; POC, point-of-care;
- 540 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation

541 Table 3: Summary of patient's emergency department (ED) length of stay (LOS)

542 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

543 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

544 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

- 545 for this study and are included in this summary table.
- 546 ^aWilcoxon rank-sum test
- 547 b Test excludes 'Invalid/other' category
- 548 PCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-

549 CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the

- 550 intervention period
- 551 ^d There were no data in the control period and only one record in the intervention period for 'Other'

552 disposition category. ED LOS summary statistics for 'Other' disposition category were therefore not

- 553 calculated
- 554 ICU, intensive care unit; IQR, interquartile range; N/A, not applicable; PCR, polymerase chain
- 555 reaction; POC, point-of-care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD,
- 556 standard deviation

557 Table 4: Summary of emergency department (ED) disposition

558 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

559 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

- 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible
- 561 for this study and are included in this summary table.
- 562 ^a Chi-square test. Subgroup p-values were adjusted for multiplicity using the false discovery rate
- method
- **b Test excludes 'Other' disposition category**
- 565 [°]PCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-
- CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the
- intervention period
- ICU, intensive care unit; N/A, not applicable; PCR, polymerase chain reaction; POC, point-of-care;
- SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

571 Table 5: Summary of anti-infective prescriptions

572 One patient may receive multiple anti-infective prescriptions per visit. Antibiotic or antiviral

573 prescriptions are counted as one instance per visit. All individuals with symptoms of a possible SARS-

574 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

575 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

576 for this study and are included in this summary table.

577 ^a Chi-square test. Subgroup p-values were adjusted for multiplicity using the false discovery rate

578 method

579 PCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-

580 CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the

- 581 intervention period
- 582 ^{There were no data in the control period and only one record in the intervention period for 'Other'}
- 583 disposition category. ED LOS summary statistics for 'Other' disposition category were therefore not
- 584 calculated

- 585 ED, emergency department; ICU, intensive care unit; N/A, not applicable; PCR, polymerase chain
- 586 reaction; POC, point-of-care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

